A detailed history of Black Rock Inc. transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,875,425 shares of ATNM stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,875,425
Previous 1,708,988 9.74%
Holding current value
$2.29 Million
Previous $13.4 Million 3.71%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.56 - $9.89 $1.09 Million - $1.65 Million
166,437 Added 9.74%
1,875,425 $13.9 Million
Q1 2024

May 10, 2024

BUY
$5.0 - $9.2 $85,370 - $157,080
17,074 Added 1.01%
1,708,988 $13.4 Million
Q4 2023

Feb 13, 2024

SELL
$4.02 - $6.08 $293,387 - $443,730
-72,982 Reduced 4.14%
1,691,914 $8.59 Million
Q3 2023

Nov 13, 2023

BUY
$5.91 - $7.37 $391,395 - $488,085
66,226 Added 3.9%
1,764,896 $10.4 Million
Q2 2023

Aug 11, 2023

BUY
$7.15 - $9.39 $8.23 Million - $10.8 Million
1,151,187 Added 210.27%
1,698,670 $12.6 Million
Q1 2023

May 12, 2023

BUY
$8.51 - $14.26 $553,839 - $928,055
65,081 Added 13.49%
547,483 $5.17 Million
Q4 2022

Feb 13, 2023

BUY
$7.05 - $14.41 $1.62 Million - $3.31 Million
229,548 Added 90.78%
482,402 $5.14 Million
Q3 2022

Nov 14, 2022

BUY
$4.81 - $8.48 $101,192 - $178,402
21,038 Added 9.08%
252,854 $1.87 Million
Q2 2022

Aug 12, 2022

BUY
$4.71 - $7.11 $4,078 - $6,157
866 Added 0.37%
231,816 $1.11 Million
Q1 2022

May 12, 2022

BUY
$4.57 - $6.4 $11,964 - $16,755
2,618 Added 1.15%
230,950 $1.18 Million
Q4 2021

Feb 10, 2022

BUY
$6.01 - $8.8 $54,624 - $79,983
9,089 Added 4.15%
228,332 $1.37 Million
Q3 2021

Nov 09, 2021

SELL
$5.76 - $9.67 $18,944 - $31,804
-3,289 Reduced 1.48%
219,243 $1.94 Million
Q2 2021

Aug 11, 2021

BUY
$7.01 - $8.63 $1.56 Million - $1.92 Million
222,532 New
222,532 $1.76 Million

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $30.7M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.